Immunohistochemical (IHC) testing for estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor −2 (HER-2) is now carried out on the tissue samples of all newly diagnosed patients with invasive breast cancer in the vast majority of hospital laboratories [1, 2]. Here, ERBB2 is linked to invasive breast carcinoma.